Author Archive

You are here: / Francesco Del Giudice, Costantino Leonardo, Giuseppe Simone, Martina Pecoraro,...
Francesco Del Giudice, Costantino Leonardo, Giuseppe Simone, Martina Pecoraro, Ettore De Berardinis, Stefano Cipollari, Simone Flammia, Marco Bicchetti, Gian Maria Busetto, Benjamin I. Chung, Michele Gallucci, Carlo Catalano, Valeria Panebianco

About Francesco Del Giudice, Costantino Leonardo, Giuseppe Simone, Martina Pecoraro, Ettore De Berardinis, Stefano Cipollari, Simone Flammia, Marco Bicchetti, Gian Maria Busetto, Benjamin I. Chung, Michele Gallucci, Carlo Catalano, Valeria Panebianco

This author has not written his bio yet.
But we are proud to say that Francesco Del Giudice, Costantino Leonardo, Giuseppe Simone, Martina Pecoraro, Ettore De Berardinis, Stefano Cipollari, Simone Flammia, Marco Bicchetti, Gian Maria Busetto, Benjamin I. Chung, Michele Gallucci, Carlo Catalano, Valeria Panebianco contributed 1479 entries already.
Edit the profile description here.

Entries by Francesco Del Giudice, Costantino Leonardo, Giuseppe Simone, Martina Pecoraro, Ettore De Berardinis, Stefano Cipollari, Simone Flammia, Marco Bicchetti, Gian Maria Busetto, Benjamin I. Chung, Michele Gallucci, Carlo Catalano, Valeria Panebianco

Preoperative detection of Vesical Imaging‐Reporting and Data System (VI‐RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease?

/by

Abstract We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no […]

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer

/by

Abstract We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no […]

Complications after open and robot‐assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial

/by

Abstract We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no […]

Recurrence and Progression Free Survival of Intermediate Risk Non‐Muscle Invasive Bladder Cancer: The impact of Conditional Evaluation and Sub‐Classification

/by

Abstract We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no […]

Evidence‐Based Quality and Accuracy of YouTube Videos about Nephrolithiasis

/by

Abstract We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no […]

© 2024 BJU International. All Rights Reserved.